Conference Roundup

Study finds TTHX1114 enhances visual recovery, corneal deturgescence after DSO

TTHX1114, an engineered FGF1, when administered in a dose-responsive manner, can enhance the rate of visual recovery and corneal deturgescence following Descemet stripping only (DSO), according to data presented at ASCRS 2023. Smaller descemetorhexis was associated with a faster recovery, while the presence of comorbid diabetes appeared to delay recovery....